Landmark award for Greater Manchester’s devolved health system – £28.5m invested to pioneer lifesaving research and new treatments
Today history has been made as a single Manchester
bid has been awarded £28.5m from the NIHR, bringing lifesaving
tests and treatments a step nearer for millions of people.
The bid has only been made possible through bringing together
the recognised clinical and research expertise from across health
and academia, which demonstrates the connectivity and collaboration
that is central to making Greater Manchester devolution a
The successful bid has been hosted by Central Manchester
University Hospitals NHS Foundation Trust, in partnership with The
University of Manchester and the partnership also involves The
Christie NHS Foundation Trust, Salford Royal NHS Foundation Trust,
University Hospital of South Manchester NHS Foundation Trust and is
supported by Manchester Academic Health Science Centre. It will see
Manchester granted prestigious NIHR Biomedical Research Centre
This will drive forward pioneering research into new tests and
treatments in the areas of musculoskeletal disease, hearing health,
respiratory disease and dermatology and three cancer themes
(prevention, radiotherapy and precision medicine).
Manchester's researchers impressed an international panel of
experts with their unique proposals that will accelerate the
translation of early stage research into new diagnostic tests and
treatments to benefit patients of all ages and backgrounds in
Greater Manchester and beyond. This will make Manchester ideally
placed to attract further research investment that will give our
patients early access to new and ground-breaking treatments and
will deliver wider value to the economy.
Jon Rouse, Chief Officer of Greater Manchester Health and Social
Care Partnership, the body overseeing the devolution of the £6bn
health and social care budget, said:
"The new partnership approach under devolution means that we
have both the opportunity - and the means - to combine the talents
of people from a whole range of areas to benefit our population.
This hugely welcome funding is recognition that in Greater
Manchester we can combine the best clinical skills with the best
research, innovation and academic talent to take huge steps in
improving the health and wellbeing of our people.'
Professor Ian Bruce (right), Director of the NIHR
Manchester BRC, added: "Working closely with patients, we will use
the latest advances in biology, medicine and health technology to
better predict disease and likely treatment response. The new
diagnostic tests and therapies we develop will enable doctors to
offer a more tailored approach and to better personalise treatments
to the individual. We are also working on better ways to prevent
disease developing in the first place."
Sir Mike Deegan, Chief Executive of Central Manchester
University Hospitals NHS Foundation Trust, explained: "The
achievement of a BRC for Manchester is a landmark moment which will
see £28.5m directly invested into finding new ways of preventing,
predicting and treating some of the major causes of premature death
and disability," commented "Bringing together our research
expertise has only been made possible by the unique connectivity
which devolution provides."
Professor Dame Nancy Rothwell, President & Vice-Chancellor
at The University of Manchester, said: "The BRC focuses the
research efforts of the University and NHS Partners so that we can
address the considerable health needs of Greater Manchester.
As the areas of research being targeted by the BRC represent
complex global health issues our work also has the potential to
have an impact much further afield."
Roger Spencer, Chief Executive of The Christie, said: "Having a
BRC that focuses on three areas of cancer research is to be warmly
welcomed. Together with cutting edge advances in treatment such as
the new proton beam therapy unit, The Christie is improving
research into cancer which means we will be even better able to
serve the health needs of this region."
For further information please contact:
(0782 514 2219)
Professor Ian Bruce, BRC Director, is available for interview on
Wednesday 14th September by contacting Emma Smith
Patient, Sandhya who has participated in a research study (see
patient story) is available for interview on Wednesday
14th September before 9.30 or after 17.00 by contacting
Emma Smith (details above)
NOTES TO EDITORS
The NIHR Manchester Biomedical Research Centre
(MBRC) is a partnership between Central Manchester
University Hospitals NHS Foundation Trust (CMFT) and The University
of Manchester (UoM).
The MBRC brings together expertise from across the city to
accelerate new discoveries through translational research that will
improve health. The BRC delivery partners are: CMFT; Salford
Royal NHS Foundation Trust; The Christie Hospital NHS Foundation
Trust (The Christie); The University of Manchester; and University
Hospital of South Manchester NHS Foundation Trust (UHSM).
Supported by the Manchester Academic Health Science Centre, the
MBRC will help clinicians to move towards more proactive approach
to medicine by applying P4 principles:
- Prevent disease;
- Predict disease progression;
- Personalise treatment pathways;
- Empower patients to Participate in their
The NIHR has awarded £28.5m to CMFT over five years from 1 April
2017, to fund MBRC research posts and biomedical studies in the
Theme 1: Musculoskeletal
Musculoskeletal disorders, such as arthritis and connective
tissue diseases, account for over 20% of all GP consultations and
are the second most common cause of disability worldwide.
Building on the work of our NIHR Manchester Musculoskeletal
Biomedical Research Unit, the BRC will focus on strategies to
prevent arthritis developing in the first place. We are also
developing new treatment approaches to arthritis in adults and
children and new tests to improve our ability to personalise
treatments used. .
Theme 2: Hearing
Hearing loss will soon be the 7th largest global
disease burden. It represents a major public health issue
with substantial economic and societal costs. The BRC is
focused on the rapid adoption of discoveries into routine clinical
practice to improve health and wellbeing, reduce inequalities and
provide value for money.
The BRC will help deliver effective and efficient hearing health
across the lifespan - from preventing potentially devastating
inherited deafness through to age-related deafness.
Theme 3: Respiratory
Respiratory diseases are the third most common cause of death
and the second most common cause of hospital admissions in the
The BRC will build a better understanding of the underlying
causes of respiratory conditions and test new drug compounds aimed
at novel targets to modify the disease processes involved and
improve symptom control in patients.
Research will focus on earlier diagnosis and more targeted
treatment, to maximise the likelihood of a good treatment response
for an individual whilst minimising the risks of harm from
therapies such as antimicrobial resistance.
Theme 4: Cutaneous
inflammation and repair
Professor Chris Griffiths
Skin conditions and poor wound healding have a considerable
impact on many people's quality of life.
The BRC will identify markers and tools, which can be used to
personalise treatment plans and identify opportunities to address
unmet clinical need for patients suffering from complex wounds,
psoriasis, hair loss and light-sensitive conditions.
Theme 5: Cancer Prevention and Early
Around 50% of people in the UK will be diagnosed with cancer in
their lifetime. Cancer prevention and early detection
strategies are not currently fully leveraged despite having an
important role to play in the fight against cancer.
The BRC will help to improve the targeting of these strategies,
by developing the early markers needed to diagnose cancer sooner
and rapidly identify whether a treatment is having the desired
Theme 6: Advanced radiotherapy
Professor Catharine West
Radiotherapy has an important role to play in the fight against
cancer. Around 40% of those patients cured of cancer have
received radiotherapy as part of their treatment.
The BRC will improve the delivery of radiation and develop
markers to predict the benefit of different types of radiation and
drug-radiation combinations, as well as the risk of long-term side
Cancer precision medicine
Professor Caroline Dive
The BRC will help the NHS to deliver a more personalised and
proactive approach to caring for patients with cancer.
Through the precise characterisation of tumours, its research will
enable us to develop the diagnostic tests needed to match an
individual's cancer with the drug most likely to have the
desired therapeutic effect.
Work will also focus on helping clinicians to anticipate and
appropriately manage drug resistant relapse, a common problem faced
by patients with cancer.
Central Manchester University Hospitals NHS Foundation
Trust is a leading provider of specialist healthcare
services in Manchester, treating more than a million patients every
year. Its seven specialist hospitals (Manchester Royal Infirmary,
Saint Mary's Hospital, Royal Manchester Children's Hospital,
Manchester Royal Eye Hospital, University Dental Hospital of
Manchester, Trafford General and Altrincham Hospitals) and
community services are home to hundreds of world class clinicians
and academic staff committed to finding patients the best care and
treatments. For more information, go to www.cmft.nhs.uk and www.research.cmft.nhs.uk.
About The University of Manchester
The University of Manchester, a member of the prestigious
Russell Group, is the UK's largest single-site university with
38,600 students. It has 20 academic schools and hundreds of
specialist research groups undertaking pioneering,
multi-disciplinary teaching and research of worldwide
significance. The University is one of the country's
major research institutions, rated fifth in the UK in terms of
'research power' (REF 2014), and has had no fewer than 25 Nobel
laureates either work or study there. The University had an annual
income of just over £1 billion in 2014/15. Visit
www.manchester.ac.uk for further information.
Cancer is one of The University of Manchester's
research beacons - examples of pioneering discoveries,
interdisciplinary collaboration and cross-sector partnerships that
are tackling some of the biggest questions facing the planet.
Manchester Academic Health Science Network:
The Department of Health accredited Manchester Academic Health
Science Centre helps to improve the health of Greater Manchester's
2.8 million population through the integration of leading research,
excellence in medical and healthcare education, and outstanding
Focusing on Precision Medicine, Experimental Medicine and Health
Informatics enables the translation of research into practice at
scale and pace as part of the drive to deliver better health
outcomes and economic growth.
MAHSC is one of six academic health science centres in England.
Its partners are The University of Manchester, Central
Manchester University Hospitals NHS Foundation Trust, the
Manchester Mental Health and Social Care Trust, Salford Clinical
Commissioning Group, Salford Royal NHS Foundation Trust, The
Christie NHS Foundation Trust, and University of South Manchester
NHS Foundation Trust. For more information visit:
The Christie opened in 1901 and is now one of
Europe's leading cancer centres and the largest single-site centre
in Europe. It has one of the largest radiotherapy departments
in the world as well as centres in Oldham and Salford. It
also houses the UK's largest brachytherapy service. The Christie
delivers chemotherapy treatment through the largest chemotherapy
unit in the UK, as well as via 10 other sites, a mobile
chemotherapy unit and in patients' homes. The Christie is ranked as
the 9th most technologically advanced cancer centre in the world
and the top centre outside North America. Our NIHR Clinical
Research Facility is a large, high quality, dedicated clinical
research environment where our patients can participate in complex
and early phase clinical trials. Around 600 clinical trials may be
taking place at any one time. New developments include the UK's
first NHS high energy proton beam therapy service, due to start
treating patients in 2018. The Christie's School of Oncology
provides undergraduate education, clinical professional and medical
education - the first of its kind in the UK.
Salford Royal NHS Foundation Trust aims to be
the safest organisation in the NHS through providing safe, clean
and personal care to every patient, every time. We are an
integrated provider of hospital, community and primary care
services, including the University Teaching Trust. Our team of
7,000 staff provide local services to the City of Salford and
specialist services to Greater Manchester and beyond. We are
an Outstanding Trust - the first Trust in the North of England to
achieve the highest rating given by the Care Quality
About University Hospital of South Manchester NHS
Foundation Trust (UHSM):
UHSM is a major acute teaching hospital trust providing services
for adults and children at Wythenshawe Hospital and Withington
Community Hospital and Community Services. We are recognised as a
centre of clinical excellence in a number of specialist areas and
provide district general hospital services and specialist tertiary
services to our local community.
The National Institute for Health Research
(NIHR) is funded by the Department of Health to improve
the health and wealth of the nation through research. The NIHR is
the research arm of the NHS. Since its establishment in April 2006,
the NIHR has transformed research in the NHS. It has increased the
volume of applied health research for the benefit of patients and
the public, driven faster translation of basic science discoveries
into tangible benefits for patients and the economy, and developed
and supported the people who conduct and contribute to applied
health research. The NIHR plays a key role in the Government's
strategy for economic growth, attracting investment by the
life-sciences industries through its world-class infrastructure for
health research. Together, the NIHR people, programmes, centres of
excellence and systems represent the most integrated health
research system in the world. For further information, visit the
NIHR website (www.nihr.ac.uk).